JP2013522369A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522369A5
JP2013522369A5 JP2013501398A JP2013501398A JP2013522369A5 JP 2013522369 A5 JP2013522369 A5 JP 2013522369A5 JP 2013501398 A JP2013501398 A JP 2013501398A JP 2013501398 A JP2013501398 A JP 2013501398A JP 2013522369 A5 JP2013522369 A5 JP 2013522369A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
biological condition
formula
lack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501398A
Other languages
English (en)
Japanese (ja)
Other versions
JP5770261B2 (ja
JP2013522369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029432 external-priority patent/WO2011119610A2/en
Publication of JP2013522369A publication Critical patent/JP2013522369A/ja
Publication of JP2013522369A5 publication Critical patent/JP2013522369A5/ja
Application granted granted Critical
Publication of JP5770261B2 publication Critical patent/JP5770261B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501398A 2010-03-23 2011-03-22 （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３ Expired - Fee Related JP5770261B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31663110P 2010-03-23 2010-03-23
US61/316,631 2010-03-23
PCT/US2011/029432 WO2011119610A2 (en) 2010-03-23 2011-03-22 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3

Publications (3)

Publication Number Publication Date
JP2013522369A JP2013522369A (ja) 2013-06-13
JP2013522369A5 true JP2013522369A5 (enExample) 2014-05-08
JP5770261B2 JP5770261B2 (ja) 2015-08-26

Family

ID=44170321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501398A Expired - Fee Related JP5770261B2 (ja) 2010-03-23 2011-03-22 （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３

Country Status (7)

Country Link
US (1) US8604009B2 (enExample)
EP (1) EP2556053B1 (enExample)
JP (1) JP5770261B2 (enExample)
AU (1) AU2011232633B2 (enExample)
CA (1) CA2794006C (enExample)
ES (1) ES2545403T3 (enExample)
WO (1) WO2011119610A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884039B2 (en) 2012-05-30 2014-11-11 Wisconsin Alumni Research Foundation Crystallization of (20R) and (20S) analogs of 2-methylene-19-nor-24-dimethyl-1α,25-dihydroxyvitamin D3
JP2015522015A (ja) 2012-06-29 2015-08-03 ウイスコンシン アラムニ リサーチ ファンデーション 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用
US9539231B2 (en) 2014-01-17 2017-01-10 The Regents Of The University Of Colorado, A Body Corporate Method for treating triple-negative breast cancer using AMPI-109
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
JPH0695892B2 (ja) 1990-01-12 1994-11-30 伊藤忠飼料株式会社 体脂肪の畜積量を減少させる飼料
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
JP3210156B2 (ja) 1993-10-18 2001-09-17 マツダ株式会社 自動車の前部車体構造
US5552392A (en) 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6392071B1 (en) 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6114317A (en) 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
ATE344039T1 (de) 1999-04-01 2006-11-15 Univ Johns Hopkins Nicht-calcemische, transkriptionell-aktive, schwefelhaltige analoga von 1-alpha, 25- dihydroxyvitamin d3 mit antiproliferativer wirkung
AU6527201A (en) 2000-05-31 2001-12-11 Wisconsin Alumni Res Found 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CN1217664C (zh) 2000-07-14 2005-09-07 威斯康星校友研究基金会 2－亚甲基－19－去甲－20(S)－1α，25－二羟维生素D3增加骨强度的用途
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
JP4022144B2 (ja) 2000-09-08 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用
US6835723B2 (en) 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2003084925A1 (en) 2002-03-29 2003-10-16 Wisconsin Alumni Research Foundation METHOD OF SYNTHESIZING 1α-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL
US6846811B2 (en) 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US6894037B2 (en) 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
WO2005018658A1 (en) 2003-08-20 2005-03-03 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds
WO2005027913A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005027931A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
MXPA06003122A (es) 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2005027929A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
WO2005027915A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US7214670B2 (en) 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8188064B2 (en) 2003-11-25 2012-05-29 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
US7053075B2 (en) 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US7915242B2 (en) 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
ATE469883T1 (de) 2004-11-22 2010-06-15 Wisconsin Alumni Res Found 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon
JP2008520703A (ja) 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用
WO2006057884A2 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
CA2588415C (en) 2004-11-22 2012-07-10 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
MX2007006544A (es) 2004-11-22 2007-07-25 Wisconsin Alumni Res Found 2-metilen-18,19-dinor-1a-hidroxi-homopregnacalciferol y sus usos.
WO2006057914A2 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
DK1848442T3 (da) 2005-02-11 2012-05-29 Wisconsin Alumni Res Found 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
US7563783B2 (en) 2005-02-11 2009-07-21 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
JP2008538214A (ja) 2005-03-29 2008-10-16 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２３Ｓ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトンおよび２−メチレン−１９−ノル−（２３Ｒ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトン
US7241909B2 (en) 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
JP2009533483A (ja) 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
MX2008012673A (es) 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-19, 21-dinorvitamina d3 y sus usos.
EP2046737B1 (en) 2006-04-06 2011-09-07 Wisconsin Alumni Research Foundation 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
WO2008039754A1 (en) 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
AU2008345084A1 (en) 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs
MX2010007266A (es) 2007-12-28 2010-11-30 Wisconsin Alumni Res Found Análogos de vitamina d, (20s)-23, 23-difluoro-2-metilen-19-nor-bis homopregnacalciferol.
EP2237837B1 (en) 2007-12-28 2012-08-22 Wisconsin Alumni Research Foundation (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
WO2009111695A1 (en) 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
CA2717362A1 (en) 2008-03-10 2009-09-17 Wisconsin Alumni Research Foundation Vitamin d compounds and methods for reducing ocular hypertension (oht)
US7888339B2 (en) 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8193170B2 (en) 2008-07-10 2012-06-05 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
US7893043B2 (en) 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8399439B2 (en) 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
EP2461815B1 (en) 2009-08-03 2014-10-22 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2776462C (en) 2009-10-02 2017-04-18 Wisconsin Alumni Research Foundation (20s,22e)-2-methylene-19-nor-22-ene-1.alpha.,25-dihydroxyvitamin d3 analogs

Similar Documents

Publication Publication Date Title
JP2009525981A5 (enExample)
JP2010505739A5 (enExample)
EP2854796B1 (en) Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer
JP2013522369A5 (enExample)
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
JP2009536191A5 (enExample)
RU2014108885A (ru) Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
JP2007502832A5 (enExample)
EP2902025A1 (en) Therapeutic agent for dyslipidemia
JP2010540555A5 (enExample)
JP2008520703A5 (enExample)
JP2016509601A5 (enExample)
JP2007504168A5 (enExample)
JPWO2014157444A1 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2006510658A5 (enExample)
CA2597624A1 (en) 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
JP2008520705A5 (enExample)
JP2008520709A5 (enExample)
JP2008520691A5 (enExample)
JP2009502777A5 (enExample)
JP2011527695A5 (enExample)
JP2013522370A5 (enExample)
JP2006523239A5 (enExample)
JP2011527699A5 (enExample)
JP2014520101A5 (enExample)